Engflag

Blopresid

Quick links to important sections

Blopresid

Blopresid_EN

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Blocking At1-Receptors, Diuretic, Hypotensive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blopresid

What is Blopresid?

Blopresid is a fixed-dose combination medication used in the management of high blood pressure, also known as hypertension. It combines two different types of active ingredients that work through distinct mechanisms to help control blood pressure levels more effectively than either component used alone.

Components of Blopresid

The medication consists of the following two active substances:

  • Candesartan cilexetil: This ingredient belongs to a class of medications called angiotensin II receptor antagonists. It works by blocking the action of angiotensin II, a naturally occurring substance in the body that causes blood vessels to tighten and narrow. By inhibiting this effect, candesartan allows blood vessels to relax and widen, which helps lower blood pressure.
  • Hydrochlorothiazide: This is a diuretic, often referred to as a water pill. It belongs to the thiazide class of medications and works by increasing the amount of salt and water removed from the body through the kidneys. This reduction in fluid volume within the blood vessels contributes to a decrease in blood pressure.

Mechanism of Action

The combination of these two agents provides a dual approach to treating hypertension. While candesartan addresses the hormonal system that regulates vascular resistance, hydrochlorothiazide addresses fluid volume. By managing both the width of the blood vessels and the volume of blood circulating through them, the medication helps to lower blood pressure levels toward a more optimal range.

Therapeutic Goal

Blopresid is typically used when treatment with a single medication has not sufficiently controlled blood pressure. Lowering high blood pressure is a preventive measure aimed at reducing the long-term strain on the heart and arteries. Consistent blood pressure management is essential for maintaining cardiovascular health and reducing the risk of associated long-term complications.

What side effects are possible with Blopresid?

Possible Side Effects and Safety Information

The regulatory documentation for the candesartan cilexetil and hydrochlorothiazide combination (Blopresid) provides a structured profile of potential adverse reactions and safety constraints in clinical use.

Adverse Reactions by Frequency and System-Organ Class

Adverse events are formally classified based on incidence rates observed in clinical settings. Common reactions, typically defined as occurring in 1% to 10% of patients, frequently involve the Nervous System and general systemic effects, including dizziness, headache, back pain, and upper respiratory tract infection. Less frequently reported reactions fall into the Uncommon category, while events like angioedema, blood disorders, and hepatic dysfunction are considered Very Rare and generally identified through post-marketing surveillance.

Classification Examples of Reactions
Common Dizziness, headache, back pain, nausea, flu-like symptoms
Uncommon/Rare Vomiting, pancreatitis, angioedema, acute renal failure

Serious Safety Considerations

The regulatory profile mandates specific warnings for serious adverse reactions. These include angioedema, a potentially life-threatening swelling reaction, and Symptomatic Hypotension, a severe drop in blood pressure most likely to occur at the start of therapy. Additionally, the label specifies a risk of Acute Angle-Closure Glaucoma and an increased risk of Non-Melanoma Skin Cancer (NMSC) associated with long-term exposure to the hydrochlorothiazide component.

Population-Specific Restrictions

Official safety documentation defines specific populations for whom the medicine is contraindicated. These restrictions include use during the second and third trimesters of pregnancy due to the risk of fetal toxicity and death. The drug is also prohibited for patients with pre-existing conditions such as severe renal impairment (creatinine clearance less than 30 mL/min) and severe hepatic impairment or cholestasis.

Overdose and Emergency Response

Blopresid overdose manifests primarily as symptomatic hypotension, representing a significant drop in blood pressure due to the Candesartan component. The official labeling documents this core presentation, which is often accompanied by clinical signs such as dizziness and documented changes in heart rhythm, including either tachycardia (rapid) or bradycardia (slow heartbeat). Additionally, overexposure to the Hydrochlorothiazide component may lead to systemic electrolyte disturbances, particularly hypokalemia (low potassium) and hyponatremia (low sodium), alongside observable signs of dehydration and fluid imbalance.

Regulatory authorities classify overdose by its potential for severe, life-threatening outcomes, which include profound hypotension that could progress to shock. In susceptible patients, severe fluid and electrolyte disturbances carry the potential for acute renal failure or even hepatic coma.

Immediate medical attention is required for any suspected overdose or when these severe manifestations are observed. Management is officially defined as symptomatic and supportive treatment, as no specific antidote is known for Candesartan cilexetil. Supportive measures outlined in regulatory information involve procedures such as volume expansion using intravenous fluids to counteract severe hypotension, alongside the close medical monitoring of serum electrolytes and blood pressure in a hospital setting. Official documents also note that Candesartan is not removable by hemodialysis.

Therapeutic Uses of Blopresid

Quick Facts

  • Primary Use: Management of high blood pressure (hypertension).
  • Secondary Use: Symptom management for certain adult heart failure patients.
  • Therapeutic Goal: To assist in lowering blood pressure and reducing the risk of cardiovascular events.

Blopresid is a prescription medication used to assist in the long-term management of specific cardiovascular conditions. The primary therapeutic domain for Blopresid is the treatment of hypertension in adults, which refers to elevated blood pressure. Achieving and maintaining appropriate blood pressure levels is associated with a reduced potential for major cardiovascular events, such as strokes or myocardial infarctions.

It is also a treatment consideration for certain adult patients who have been diagnosed with heart failure (specifically, those classified as NYHA Class II–IV). In this context, Blopresid may be utilized to help manage symptoms and reduce the need for heart failure-related hospitalizations. This medication may be prescribed alone or in combination with other agents, as determined by a healthcare provider.

Eligibility and Restrictions for Use

Eligibility Profile

Official regulatory documents define the eligibility for Blopresid based on a patient's age, physiological state, and co-occurring health conditions or medications. Adults with essential hypertension or heart failure are generally eligible for use.

Populations Who Must Not Use Blopresid (Contraindicated)

Blopresid is strictly contraindicated in the following populations:

  • Children aged below 1 year for all indications.
  • Pregnant women during the second and third trimesters of pregnancy, as it can cause serious harm or death to the developing fetus.
  • Individuals with severe hepatic impairment and/or cholestasis (bile drainage issues).
  • Patients with a known hypersensitivity (allergy) to the active substance (candesartan cilexetil) or any other component of the product.
  • Diabetic patients who are also taking aliskiren-containing products.

Other Official Restrictions

  • Pregnancy: Use is not recommended during the first trimester.
  • Lactation: Use is not recommended during breastfeeding.
  • Concomitant Use: Co-administration with aliskiren is also contraindicated in patients with renal impairment (GFR < 60 mL/ min/1.73 m^2) due to increased risk of adverse effects.

What should I know about interactions with other medicines?

Blopresid's interaction profile is shaped by the properties of its two active components, requiring strict adherence to regulatory constraints for certain co-administrations. The combination is formally contraindicated with aliskiren in patients who have diabetes mellitus or moderate-to-severe renal impairment (GFR <60 mL/min/1.73 m^2). This prohibition is based on the increased regulatory risk of hyperkalemia, hypotension, and renal impairment when both agents block the Renin-Angiotensin-Aldosterone System.

Interactions involving electrolyte balance require specific precautions. Co-administration with Lithium is documented to increase the risk of toxicity, resulting from the diuretic component reducing lithium's renal clearance. Furthermore, the combination with potassium-sparing diuretics or potassium supplements increases the official risk of hyperkalemia.

Pharmacodynamic antagonism may occur with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen, which can diminish the blood pressure-lowering effect and increase the potential for renal impairment. Specific timing rules apply to products that modify absorption. When co-administered with bile-acid binding resins (like cholestyramine), Blopresid must be taken with a mandated time separation to prevent a reduction in the absorption of the hydrochlorothiazide component. The label also notes that the use of antidiabetic agents may require dosage adjustment, as the diuretic component can alter glucose tolerance, and alcohol may potentiate the hypotensive effect.

Mechanism of Action

How Blopresid Works: Mechanism of Action

The pharmacodynamic mechanism of Blopresid centers on the active ingredient, candesartan, which functions as a selective, non-peptide antagonist of the Angiotensin II Receptor Type 1 ( AT1). This receptor is a crucial signaling element within the Renin-Angiotensin-Aldosterone System (RAAS), located primarily on vascular smooth muscle cells, adrenal glands, and renal tissues.

By blocking AT1, candesartan prevents the binding and action of the vasoconstrictor hormone, Angiotensin II ( Ang II). This molecular interference initiates a cascade leading to two primary physiological effects. First, it suppresses Ang II-mediated vasoconstriction, promoting vasodilation and a subsequent decrease in peripheral vascular resistance. Second, the dampening of Ang II signaling reduces aldosterone release and alters renal activity, contributing to decreased sodium and fluid retention. These combined actions modulate the overall circulatory volume and pressure dynamics.

Dosage and Administration Information

Blopresid (candesartan cilexetil/hydrochlorothiazide) is a fixed-dose combination product intended for oral administration as a tablet. Its use is structured as a maintenance and replacement therapy, not as a starting treatment for hypertension. The combination is designed to be utilized after successful individual dose titration or for patients whose blood pressure remains uncontrolled on monotherapy.

The medication is administered once daily, with administration time being flexible as the tablet may be taken with or without food. Standard approved strengths are 16 mg/12.5 mg, 32 mg/12.5 mg, and 32 mg/25 mg (candesartan/HCTZ), with the highest strength representing the maximum recommended daily dose.

Existing volume and/or salt depletion must be corrected prior to initiating therapy with this fixed combination. For established users, dose adjustments, when warranted, should be separated by intervals of approximately four weeks to allow for the full effect of the new dose to be attained. Specific adjustments are typically not required for older adults; however, the product is contraindicated in severe renal or hepatic impairment and has not had its use established in pediatric patients. If a dose is missed, a double dose is not taken, and the regular schedule is resumed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Blopresid

Research Evidence for Managing High Blood Pressure

The primary evidence base for Blopresid was studied for the management of high blood pressure (hypertension). This research has mostly relied on Randomized Controlled Trials (RCTs), where the fixed-dose combination was evaluated in comparison to an inactive substance (placebo) or against the individual ingredients (candesartan alone or the diuretic component alone). The main measurements research examined were the patient's Systolic and Diastolic Blood Pressure (SBP/DBP) readings. In these short-term studies, data show patterns related to lower average blood pressure measurements in the combination groups compared to the individual components or placebo. Studies reported that a higher proportion of observed patients attained specific target blood pressure goals established by the study protocol.

However, the majority of the pivotal trials research explored primarily focused on the short-term change in blood pressure. Therefore, there is limited information for long-term outcomes specifically comparing this fixed combination against other dual-agent therapies for the endpoint of preventing major cardiovascular events.

Research Evidence for Supporting Heart Failure Management

Blopresid was also evaluated in contexts relevant to certain adult patients with heart failure. The foundation for this use is largely drawn from long-term RCTs that studied the single-ingredient candesartan. These large studies research examined outcomes related to systemic or functional imbalance and episodic or acute changes, such as outcomes related to heart failure-related hospitalizations and outcomes related to changes in a patient's functional capacity.

What is Still Uncertain About Blopresid Research

While the existing research contributes to the broader evidence landscape, there are several areas where certainty remains low or where more research is needed. Long-term effects are not fully established specifically for the Blopresid fixed combination versus other combinations. A key limitation is the reliance on blood pressure reduction as a surrogate endpoint in many combination studies, meaning the data do not directly measure the prevention of clinical events over decades. Evidence quality varies across studies, and results apply only to the populations studied, meaning research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Blopresid (FAQ)

Q: Is it safe to drink alcohol while taking this medicine?

A: According to the official product information, it is generally advised against drinking alcohol while taking Blopresid. Combining alcohol with this medication may increase central nervous system (CNS) side effects, such as feelings of sleepiness and dizziness, making them more pronounced.

Q: What is the official warning regarding pregnancy or breastfeeding?

A: The drug's official label contains a warning about pregnancy, indicating that the medication may pose a risk to an unborn baby. For patients who are breastfeeding, the official information indicates that breastfeeding is generally not recommended while using Blopresid.

Q: Does this medicine make you sleepy?

A: Yes, sleepiness is listed as a known effect of this medication. Official studies and regulatory documents list somnolence (drowsiness) as a very common adverse reaction experienced by patients during clinical trials. Patients should be mindful of this possibility.

Q: Is it safe long-term?

A: Official information indicates that serious adverse reactions, such as severe allergic reactions like angioedema, have been reported. These events have occurred in patients receiving Blopresid during both initial treatment and chronic (long-term) treatment. Patients should remain aware of the potential for these effects throughout treatment.

Q: Can children 2 years old use it?

A: The official uses of Blopresid vary depending on the condition being treated. For the indication of partial-onset seizures, the drug is approved for use in pediatric patients as young as 1 month of age. However, for other conditions like neuropathic pain or fibromyalgia, the use may be limited to older patients or adults only. It is important to review the specific approved label for the condition being treated.

How should Blopresid be stored and disposed of?

How to Store and Dispose of Blopresid

Official regulatory labeling dictates specific conditions for storing and disposing of Blopresid (candesartan cilexetil/hydrochlorothiazide) tablets to maintain product stability and ensure public safety.

Storage Requirements

  • Temperature and Environment: The medicine must be stored between 15 and 30°C (controlled room temperature). It must be protected from heat, moisture, and direct light, and it is required to keep from freezing.
  • Container: The tablets should be stored in a closed container to ensure integrity.
  • Child Safety: It is mandatory to keep Blopresid out of the reach of children.

Disposal Instructions

  • Outdated Medicine: The medicine must not be used after the expiry date and do not keep outdated medicine.
  • Discarding: Unused or expired tablets must not be thrown away in household waste or wastewater. Patients must ask a healthcare professional how to properly dispose of the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Blopresid found in:

A-Z Index: